|
|
|
|
|
|
|
|
|
|
Blogger's Note: this Lancet Oncology article is subscriber based ($$$)
Commentary
The Lancet Oncology, Early Online Publication, 7 March 2012
Commentary
The Lancet Oncology, Early Online Publication, 7 March 2012
Oestrogen and breast cancer: results from the WHI trial
"In The Lancet Oncology , the Women's Health Initiative (WHI) investigators report 1 that receipt of conjugated equine oestrogen for a median of 5·9 years reduced the risk of invasive breast cancer by 23% compared with placebo (151 cases in 5310 women who received oestrogen vs 199 cases in 5429 controls; p=0·02). Women who did develop breast cancer after receipt of oestrogen had significantly reduced breast cancer-specific mortality (six deaths in the oestrogen group vs 16 deaths in controls; p=0·03) and ..."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.